Promoted Content
Promoted Content

Find Neurology Drugs in Phase II Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Azeliragon

            Therapeutic Area: Neurology Product Name: TTP488

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Lincoln Park Capital Fund

            Deal Size: $47.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement November 24, 2020

            Details:

            vTv intends to use the net proceeds from the transaction for general corporate purposes and to support mechanistic study of TTP399 in type 1 diabetes, and conducting a multiple-ascending dose study of HPP737 as an oral therapy for psoriasis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cannabidiol

            Therapeutic Area: Neurology Product Name: ZYN002

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 23, 2020

            Details:

            Poster titled "ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Developmental and Epileptic Encephalopathies: An Open‐label Clinical Trial BELIEVE (ZYN2-CL-25)" will be presented at the American Epilepsy Society annual meeting.